Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
European Journal of Cancer2017Vol. 86, pp. 115–124
Citations Over TimeTop 10% of 2017 papers
Teresa M. Petrella, Caroline Robert, Erika Richtig, Wilson H. Miller, Giuseppe Masucci, Euan Walpole, Célèste Lebbé, Neil Steven, Mark R. Middleton, Darcy A. Hille, Wei Zhou, Nageatte Ibrahim, Jonathan Cebon
Related Papers
- → Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma(2017)88 cited
- → Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006(2021)15 cited
- → Pembrolizumab in a BRAF -Mutant Metastatic Melanoma Patient Following a Severe Immune-Related Adverse Event with Ipilimumab(2016)8 cited
- → A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma(2022)
- → Data from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab(2023)